STRATA Skin Sciences, Inc.

NasdaqCM:SSKN Stock Report

Market Cap: US$12.7m

STRATA Skin Sciences Valuation

Is SSKN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SSKN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SSKN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SSKN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SSKN?

Key metric: As SSKN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SSKN. This is calculated by dividing SSKN's market cap by their current revenue.
What is SSKN's PS Ratio?
PS Ratio0.4x
SalesUS$32.68m
Market CapUS$12.72m

Price to Sales Ratio vs Peers

How does SSKN's PS Ratio compare to its peers?

The above table shows the PS ratio for SSKN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.5x
HLTH Cue Health
0.2x38.4%US$14.7m
AWH Aspira Women's Health
1.3x57.8%US$12.0m
VASO Vaso
0.3xn/aUS$22.7m
TRIB Trinity Biotech
0.2x11.8%US$11.5m
SSKN STRATA Skin Sciences
0.4x8.0%US$12.7m

Price-To-Sales vs Peers: SSKN is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does SSKN's PS Ratio compare vs other companies in the US Medical Equipment Industry?

54 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.3x8.2%
SSKN STRATA Skin Sciences
 0.4x8.0%US$12.72m
EMBC Embecta
0.7x1.3%US$797.44m
INGN Inogen
0.7x4.2%US$223.42m
SSKN 0.4xIndustry Avg. 3.3xNo. of Companies54PS03.26.49.612.816+
54 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.3x17.1%
SSKN STRATA Skin Sciences
 0.4x58.3%US$12.72m
No more companies

Price-To-Sales vs Industry: SSKN is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Medical Equipment industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is SSKN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SSKN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: SSKN is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$61.43

7D

4.4%

1Y

-17.1%

Patterson Companies

US$1.8b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$21.62

7D

3.4%

1Y

-32.2%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.35

7D

17.6%

1Y

102.0%